the Safety and Efficacy of Intravitreal Injection of Tpdelansbsalbac in Malignant Effusions.

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
This is a Phase I/II, open, first-in-human (FIH) study of Transebacillus in Patients with malignant pleural and abdominal effusions. It consists of Phase Ia to determine the Maximum tolerated dose (MTD) or Recommended Phase 2 dose (RP2D) of Transebacillus, and Phase Ib/II to explore and confirm the efficacy, safety and Tolerability.
Epistemonikos ID: fa73b7dc0afa59be978e7edcac5dd20b50b917cc
First added on: May 15, 2024